MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors.
Ontology highlight
ABSTRACT: The Aurora kinases are essential for cell mitosis, and the dysregulation of Aurora A and B have been linked to the etiology of human cancers. Investigational agents MLN8054 (8) and alisertib (MLN8237, 10) have been identified as high affinity, selective, orally bioavailable inhibitors of Aurora A that have advanced into human clinical trials. Alisertib (10) is currently being evaluated in multiple Phase II and III clinical trials in hematological malignancies and solid tumors.
PROVIDER: S-EPMC4468408 | BioStudies |
REPOSITORIES: biostudies
ACCESS DATA